Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
详细信息 查看全文
- 作者：Federico Cappuzzoa ; f.cappuzzo@googlemail.com" class="auth_mail" title="E-mail the corresponding author ; Alessandro Morabitob ; a.morabito@istitutotumori.na.it" class="auth_mail" title="E-mail the corresponding author ; Nicola Normannoc ; n.normanno@istitutotumori.na.it" class="auth_mail" title="E-mail the corresponding author ; Paolo Bidolid ; p.bidoli@hsgerardo.org" class="auth_mail" title="E-mail the corresponding author ; Alessandro Del Contee ; alessandro.delconte@aas5.sanita.fvg.it" class="auth_mail" title="E-mail the corresponding author ; Laura Giannettaf ; laura.giannetta@ospedaleniguarda.it" class="auth_mail" title="E-mail the corresponding author ; Agnese Montaninob ; a.montanino@istitutotumori.na.it" class="auth_mail" title="E-mail the corresponding author ; Francesca Mazzonig ; francescamazzoni@hotmail.com" class="auth_mail" title="E-mail the corresponding author ; Roberta Buosih ; r.buosi@maggioreosp.novara.it" class="auth_mail" title="E-mail the corresponding author ; Marco Angelo Burgioi ; marco.burgio@irst.emr.it" class="auth_mail" title="E-mail the corresponding author ; Giulio Cereaf ; giulio.cerea@ospedaleniguarda.it" class="auth_mail" title="E-mail the corresponding author ; Rita Chiarij ; rita.chiari@ospedale.perugia.it" class="auth_mail" title="E-mail the corresponding author ; Diego Cortinovisd ; d.cortinovis@hsgerardo.org" class="auth_mail" title="E-mail the corresponding author ; Giovanna Finocchiarok ; giovanna.finocchiaro@cancercenter.humanitas.it" class="auth_mail" title="E-mail the corresponding author ; Luisa Foltrane ; luisa.foltran@aas5.sanita.fvg.it" class="auth_mail" title="E-mail the corresponding author ; Maria Rita Migliorinol ; ritamigliorino@tiscali.it" class="auth_mail" title="E-mail the corresponding author ; Marcello Tiseom ; mtiseo@ao.pr.it" class="auth_mail" title="E-mail the corresponding author ; Silvia Ferrarin ; silvia.ferrari@astrazeneca.com" class="auth_mail" title="E-mail the corresponding author ; Filippo De Mariniso ; p ; filippo.demarinis@ieo.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Gefitinib ; Rechallenge ; EGFR mutation ; Advanced stage NSCLC
- 刊名：Lung Cancer
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：31-37
- 全文大小：503 K
文摘
- •
Empiric rechallenge with gefitinib in third-line EGFR mutated-NSCLC is feasible.
- •
This strategy provides modest benefit for some patients.
- •
The driver of resistance to EGFR-TKI should be sought for each patient to tailor therapy.